Deferasirox + Deferasirox
Phase 2/3Completed 0 watching 0 views this week๐ Rising
65
Development Stage
โ
Pre-clinicalโ
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Liver Iron Overload
Conditions
Liver Iron Overload
Trial Timeline
Feb 1, 2003 โ Jan 1, 2008
NCT ID
NCT01033747About Deferasirox + Deferasirox
Deferasirox + Deferasirox is a phase 2/3 stage product being developed by Novartis for Liver Iron Overload. The current trial status is completed. This product is registered under clinical trial identifier NCT01033747. Target conditions include Liver Iron Overload.
Hype Score Breakdown
Clinical
22
Activity
15
Company
10
Novelty
7
Community
8
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01892644 | Phase 2 | Withdrawn |
| NCT01033747 | Phase 2/3 | Completed |
Competing Products
20 competing products in Liver Iron Overload